Ionis Pharmaceuticals, Inc. has entered a collaboration and license agreement with Suzhou Ribo Life Science Co. to develop and commercialize RNA-targeted therapeutics in China. Ionis granted Ribo a license to commercialize two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third Generation 2+ antisense drug. Ribo will be responsible for the research and drug discovery program to identify drugs that utilize Ionis’ ssRNAi technology. Ionis will...